Page last updated: 2024-12-05

trimetrexate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5583
CHEMBL ID119
CHEBI ID9737
SCHEMBL ID3983
MeSH IDM0025316

Synonyms (62)

Synonym
BIDD:GT0129
nsc 249008
nsc-249008
2, 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-
jb-11
5-methyl-6-({[3,4,5-tris(methyloxy)phenyl]amino}methyl)quinazoline-2,4-diamine
trimetrexate hydrate
D06238
trimetrexate (usan/inn)
tmq ,
5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine
nsc249008
ci-898
6-[((3,4,5-trimethoxyphenyl)amino)methyl]-5-methyl-2,4-quinazolinediamine
trimetrexate
52128-35-5
DB01157
NCGC00161419-01
trimetrexato [inn-spanish]
trimetrexatum [inn-latin]
jb 11
2,4-diamino-5-methyl-6-((3,4,5-trimethoxyanilino)methyl)quinazoline
hsdb 6545
5-methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)-2,4-quinazolinediamine
2,4-quinazolinediamine, 5-methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)-
chembl119 ,
bdbm18268
5-methyl-6-{[(3,4,5-trimethoxyphenyl)amino]methyl}quinazoline-2,4-diamine
NCGC00161419-04
NCGC00161419-03
trimetrexate [usan:inn:ban]
trimetrexatum
unii-upn4iti8t4
upn4iti8t4 ,
trimetrexato
FT-0649497
trimetrexate [vandf]
trimetrexate [who-dd]
trimetrexate [hsdb]
trimetrexate [usan]
trimetrexate [inn]
2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline
trimetrexate [mi]
gtpl7613
5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]quinazoline-2,4-diamine
2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylamino)methyl]quinazoline
NOYPYLRCIDNJJB-UHFFFAOYSA-N
SCHEMBL3983
CHEBI:9737
HY-10373
DTXSID3023714
AKOS030257627
2,4-quinazolinediamine,5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-
BCP15515
72828-03-6
5-methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)quinazoline-2,4-diamine
251301-18-5
Q7842225
A913386
F85148
MS-25931
EN300-7481403

Research Excerpts

Overview

Trametrexate (TMTX) is a dihydrofolate reductase inhibitor. It has been shown to potentiate fluorouracil (FU) cytotoxicity. Trimetrexate is an antifol that differs from methotrexate in ways that may be clinically important.

ExcerptReferenceRelevance
"Trimetrexate is a novel lipophilic folate antagonist that causes growth inhibition, inhibition of nucleic acid biosynthesis, and cytotoxicity at nanomolar concentrations in tissue cultures. "( Biochemical pharmacology of the lipophilic antifolate, trimetrexate.
Besserer, JA; Boritzki, TJ; Elslager, EF; Fry, DW; Jackson, RC; Leopold, WR; Sloan, BJ, 1984
)
1.96
"Trimetrexate (TMTX) is a dihydrofolate reductase inhibitor, which, like methotrexate (MTX), has been shown to potentiate fluorouracil (FU) cytotoxicity by increasing phosphoribosylpyrophosphate (PRPP) levels. "( Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma.
André, M; Bertino, JR; Conti, JA; Goker, E; Kemeny, N; Ragusa, K; Seiter, K; Tong, W, 1994
)
2.05
"Trimetrexate is a folinic acid analogue structurally related to methotrexate, whose primary mechanism of action is believed to be inhibition of dihydrofolate reductase. "( Trimetrexate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of Pneumocystis carinii pneumonia.
Fulton, B; McTavish, D; Wagstaff, AJ, 1995
)
3.18
"Trimetrexate is a powerful inhibitor of the dihydrofolate reductase of Pneumocystis carinii. "( Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029/0
Akil, B; Baughman, R; Boylen, CT; Davis, R; Frame, P; Hughlett, C; Nichols, L; Sattler, FR; Shelton, B; Weiss, W, 1994
)
3.17
"Trimetrexate is an agent that does not require uptake by the folate carrier transport system, a major mechanism of cellular resistance both in vitro and in vivo."( Clinical pharmacokinetics and pharmacology of trimetrexate.
DeLap, RJ; Marshall, JL, 1994
)
1.27
"Trimetrexate is an antifol that differs from methotrexate in ways that may be clinically important. "( An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma.
Elson, P; Khandakar, J; Trump, DL; Witte, RS, 1994
)
1.98
"Trimetrexate (TMTX) is an anticancer drug with potential advantages over the more commonly used antifolate, methotrexate (MTX); however, its use has been limited by severe myelosuppression. "( A gene transfer strategy for making bone marrow cells resistant to trimetrexate.
Blakley, RL; Rehg, JE; Sleep, SE; Sorrentino, BP; Spencer, HT, 1996
)
1.97
"Trimetrexate (TMQ) is a synthetic folate antagonist that has demonstrated non-cross resistance with methotrexate in preclinical screens. "( Phase II trial of trimetrexate in advanced esophageal cancer: a southwest oncology group study.
Brown, TD; Fleming, TR; Macdonald, JS; Ross, SW, 1996
)
2.07
"Trimetrexate is a nonclassical antifolate that has demonstrated antitumor activity against a number of malignancies, including those resistant to the classical antifolate methotrexate."( Trimetrexate: review and current clinical experience in advanced colorectal cancer.
Blanke, CD; Messenger, M; Taplin, SC, 1997
)
2.46
"Trimetrexate (TMTX) is a new antifolate which avoids competition for cellular uptake with folinic acid (FA). "( Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of the AIO.
Berdel, WE; Haboubi, N; Hohenberger, P; Kreuser, ED; Lochs, H; Szelényi, H; Thiel, E, 2000
)
2.14
"Trimetrexate (TMTX) is a biochemical modulator of 5-fluorouracil (5-FU) and leucovorin (LV). "( Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study.
Croles, JJ; Douma, J; Hammershaimb, L; Keizer, HJ; Lochs, H; Muller, EW; Punt, CJ; Schüller, J; Skovsgaard, T; Ten Napel, CH; Zhang, J, 2002
)
3.2
"Trimetrexate is a nonclassical folate antagonist that is active against a number of experimental murine and human tumor cell lines. "( Toxicity of the anticancer folate antagonist trimetrexate in rats.
Graziano, MJ; Kim, SN; MacDonald, JR; Watkins, JR, 1992
)
1.99
"Trimetrexate (TMTX) is a second generation antifol with predominantly nonrenal elimination and antitumor activity superior to that of methotrexate in preclinical models."( Pharmacokinetic study of trimetrexate in combination with cisplatin.
Comis, RL; Hudes, GR; LaCreta, F; Litwin, S; O'Dwyer, PJ; Tinsley, P; Walczak, J, 1991
)
1.31
"Trimetrexate (TMTX) is an analog of methotrexate and a potent inhibitor of the enzyme dihydrofolate reductase. "( A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-injection schedule.
Allegra, CJ; Balis, F; Brooks, J; Curt, GA; Drake, JC; Jenkins, J; Thomas, R; Weiss, RB, 1990
)
1.99
"Trimetrexate is a nonclassical antifol currently being tested for efficacy in cancer patients and as an antiparasitic agent against Pneumocystis carinii pneumonia in AIDS patients. "( Hypersensitivity reactions to trimetrexate.
Brown, TD; Costanza, ME; Grem, JL; King, SA, 1990
)
2.01
"Trimetrexate (TMTX) is a potent inhibitor of dihydrofolate reductase that circumvents the transport resistance seen with methotrexate and has a wide spectrum of preclinical activity. "( A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion.
Bishop, JF; Friedlander, ML; Morris, R; Olver, IN; Raghavan, D; Reece, P, 1989
)
2.05
"Trimetrexate is a nonclassical antifolate with greater preclinical antitumor activity than methotrexate. "( Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer.
Burke, MT; D'Acquisto, RW; Fanucchi, MP; Gralla, RJ; Heelan, RT; Kris, MG; Marks, LD, 1989
)
2.05
"Trimetrexate (TMQ) is a lipophilic antifolate shown to have antitumor activity in humans. "( Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate.
Arkin, H; Holland, JF; Kamen, BA; Ohnuma, T; Vallabhajosula, S, 1989
)
1.95
"Trimetrexate is a potent inhibitor of dihydrofolate reductase and has demonstrated significant antitumor activity against murine and human cell lines both in vitro and against several murine transplanted tumors. "( Determination of plasma trimetrexate levels using gas chromatography-mass spectrometry with selected-ion monitoring.
Ensminger, WD; Stetson, PL, 1986
)
2.02
"Trimetrexate is a lipid soluble dihydrofolate reductase inhibitor which, unlike methotrexate, does not depend upon the membrane folate transport system for cell entry. "( Inhibition of lymphocyte nucleic acid metabolism and antibody production by trimetrexate.
Branda, RF; Carney, JK; McCormack, JJ; Moore, AL; Perlmutter, CA, 1987
)
1.95
"Trimetrexate is a promising new lipophilic antifolate with antitumor and antimicrobial activity, which is currently undergoing clinical trials. "( Trimetrexate: a second generation folate antagonist in clinical trial.
Bertino, JR; Lin, JT, 1987
)
3.16
"Trimetrexate is a 2,4-diaminoquinazoline inhibitor of dihydrofolate reductase (DHFR) which is cytotoxic in vitro and in vivo to several tumors resistant to methotrexate. "( Trimetrexate: clinical development of a nonclassical antifolate.
DeLap, RJ; Grillo-Lopez, AJ; Hoth, DF; King, SA; Leyland-Jones, B; O'Dwyer, PJ, 1987
)
3.16
"Trimetrexate is a nonclassical folate antagonist. "( Trimetrexate as a single agent in patients with advanced head and neck cancer.
Robert, F, 1988
)
3.16
"Trimetrexate (TMQ) is a lipid-soluble quinazoline derivate of MTX that, unlike MTX, is not dependent upon membrane folate transport for cellular entry."( Suppression of B cell function by methotrexate and trimetrexate. Evidence for inhibition of purine biosynthesis as a major mechanism of action.
Blank, JA; Germolec, DR; Luster, MI; Rosenthal, GJ; Weigand, GW, 1988
)
1.25
"Trimetrexate is a lipid-soluble antifolate that has been shown in vitro to be a much more potent inhibitor of Pneumocystis carinii dihydrofolate reductase than the conventionally used inhibitor trimethoprim. "( Efficacy of trimetrexate, a potent lipid-soluble antifolate, in the treatment of rodent Pneumocystis carinii pneumonia.
Allegra, CJ; Chabner, B; Drake, J; Kennedy, S; Kovacs, JA; Masur, H; Parrillo, JE; Swan, JC, 1988
)
2.1

Effects

Trimetrexate has antitumor activity in vivo in several murine leukemia and solid tumor systems, including tumors in which methotrexate is inactive. The agent has shown promising activity in animal model systems.

ExcerptReferenceRelevance
"Trimetrexate has an extended conformation in both structures, and the quinazoline and phenyl rings are mutually perpendicular."( Trimetrexate: molecular structures and conformational similarities in two crystal forms.
Camerman, A; Camerman, N; Hempel, A, 1988
)
2.44
"Trimetrexate has antitumor activity in vivo in several murine leukemia and solid tumor systems, including tumors in which methotrexate is inactive."( Biochemical pharmacology of the lipophilic antifolate, trimetrexate.
Besserer, JA; Boritzki, TJ; Elslager, EF; Fry, DW; Jackson, RC; Leopold, WR; Sloan, BJ, 1984
)
1.24
"Trimetrexate has minimal activity against gastric adenocarcinoma in this study, and no further investigation of this agent at this dose and schedule is recommended in this disease."( Phase II trial of trimetrexate in untreated advanced gastric carcinoma. A Southwest Oncology Group study.
Hantel, A; Macdonald, JS; Pollock, T; Pugh, RP; Richman, SP; Tangen, CM, 1994
)
1.34
"Trimetrexate has as much activity as other single agents in advanced urothelial carcinoma. "( An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma.
Elson, P; Khandakar, J; Trump, DL; Witte, RS, 1994
)
1.98
"Trimetrexate has some activity against NSCLC, but its role in the future therapy of this disease is questionable."( A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group.
Ebbert, LP; Foley, JF; Gesme, DH; Hatfield, AK; Jett, JR; Krook, JE; Mailliard, JA; Maksymiuk, AW; Schreffler, DD; Su, JQ, 1993
)
1.27
"Trimetrexate has little activity in advanced renal cell carcinoma at this dose and schedule."( Trimetrexate in advanced renal cell carcinoma. An ECOG phase II trial.
Bryan, GT; Elson, P; Trump, DL; Witte, RS, 1992
)
2.45
"Trimetrexate has shown promising activity in animal model systems."( Phase II trial of trimetrexate in patients with advanced soft-tissue sarcoma.
Antman, KH; Gonin, R; Licht, JD, 1991
)
1.34
"Trimetrexate has an extended conformation in both structures, and the quinazoline and phenyl rings are mutually perpendicular."( Trimetrexate: molecular structures and conformational similarities in two crystal forms.
Camerman, A; Camerman, N; Hempel, A, 1988
)
2.44

Treatment

ExcerptReferenceRelevance
"Rats treated with trimetrexate (25 mg/kg/d) plus sulfamethoxazole (250 mg/kg/d) orally responded at least as well as rats treated with trimethoprim (50 mg/kg/d) plus sulfamethoxazole."( Efficacy of trimetrexate, a potent lipid-soluble antifolate, in the treatment of rodent Pneumocystis carinii pneumonia.
Allegra, CJ; Chabner, B; Drake, J; Kennedy, S; Kovacs, JA; Masur, H; Parrillo, JE; Swan, JC, 1988
)
0.98

Toxicity

In early phase II testing, nine of 15 patients who experienced life-threatening or fatal toxic effects from trimetrexate had albumin levels less than or equal to 3. This suggests that dihydrofolate reductase (DHFR) activity is essential for the parasite.

ExcerptReferenceRelevance
"In four phase II trials of trimetrexate given iv daily for 5 days, we noted marked variability among patients in the development of severe or life-threatening toxic effects."( Trimetrexate: predictors of severe or life-threatening toxic effects.
Eisenhauer, EA; Pater, JL; Walsh, WR; Zee, BC, 1988
)
2.01
" However, the toxic effects of piritrexim and trimetrexate suggest that dihydrofolate reductase (DHFR) activity is essential for the parasite, most probably because of the role of this enzyme in the synthesis of thymidine nucleotides via thymidylate synthase."( The toxicity of antifolates in Babesia bovis.
Bagnara, AS; Nott, SE, 1993
)
0.54
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Areas covered: There is clinical evidence which suggsest that, like other chemotherapeutic agents, not all HGOS patients are equally responsive to antifolates and do not have the same susceptibility to experience adverse drug-related toxicities."( Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.
Fanelli, M; Hattinger, CM; Picci, P; Serra, M; Tavanti, E; Vella, S, 2017
)
0.46

Pharmacokinetics

The pharmacokinetic behavior of trimetrexate was characterized by triexponential plasma disappearance, elimination primarily by biotransformation, substantial plasma protein binding, poor CSF penetration, and limited oral bioavailability. Preclinical antineoplastic activity, demonstrated schedule dependency, and data suggesting effectiveness against methotrexate-resistant cells prompted a Phase I clinical and pharmacokinetics study.

ExcerptReferenceRelevance
" The steady-state volume of distribution, Vdss, and terminal elimination half-life were significantly greater on Day 5 of TMTX-DDP compared to baseline."( Pharmacokinetic study of trimetrexate in combination with cisplatin.
Comis, RL; Hudes, GR; LaCreta, F; Litwin, S; O'Dwyer, PJ; Tinsley, P; Walczak, J, 1991
)
0.58
" The drug had a mean terminal half-life of 13 hours."( A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-injection schedule.
Allegra, CJ; Balis, F; Brooks, J; Curt, GA; Drake, JC; Jenkins, J; Thomas, R; Weiss, RB, 1990
)
0.55
" TMTX plasma concentrations were measured after the first dose and the data were fit by two- or three-compartment mammillary pharmacokinetic models."( A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics.
Donehower, RC; Ettinger, DS; Grochow, LB; Noe, DA, 1989
)
0.61
" TMTX concentrations were measured 1 and 24 hours after each dose, and the data were fit by use of a one-compartment pharmacokinetic model."( Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics.
Dole, GB; Donehower, RC; Ettinger, DS; Graham, ML; Grochow, LB; McGuire, WP; Noe, DA; Rowinsky, EK, 1989
)
0.62
" The pharmacokinetic behavior of trimetrexate was characterized by triexponential plasma disappearance, elimination primarily by biotransformation, substantial plasma protein binding, poor CSF penetration, and limited oral bioavailability."( Pharmacokinetics of trimetrexate (NSC 352122) in monkeys.
Balis, FM; Lester, CM; Poplack, DG, 1986
)
0.88
" The half-life of the terminal elimination-phase was 16."( Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics.
Baker, M; Bertino, JR; Cashmore, AR; Delap, R; Dreyer, RN; Ernstoff, M; Grillo-Lopez, A; Lin, JT; Marsh, JC; Whitfield, LR, 1987
)
0.59
" Estimates of pharmacokinetic parameters were similar when determined by either compartmental or noncompartmental methods."( Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer.
Bishop, JF; Morris, RG; Olver, IN; Raghavan, D; Reece, PA, 1987
)
0.6
"2 to 215 ml/min/m2) and half-life (2."( Pediatric phase I trial and pharmacokinetic study of trimetrexate.
Balis, FM; Belasco, J; Doherty, KM; Ettinger, LJ; Holcenberg, JS; Luks, E; Patel, R; Reaman, GH; Tan, C; Zimm, S, 1987
)
0.52
" Serial blood samples were obtained over 24 hours after dosing and analyzed for trimetrexate, dapsone, and monoacetyldapsone, and pharmacokinetic parameters were determined."( Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia.
Chatterjee, DJ; Dubé, MP; Koda, RT; Li, WY; Sattler, FR; Stansell, JD, 1999
)
0.85
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

Trimetrexate (TMTX) used in combination with cyclosporine (CsA) for prevention of acute graft-versus-host disease (GVHD) in patients undergoing allogeneic marrow transplantation.

ExcerptReferenceRelevance
" Thus, TMTX can be given with 5-FU (400 mg/m2) on a daily x 5-day bolus schedule at the 12 mg/m2 per day dose level, which was the recommended dose of TMTX as a single agent for phase II studies using the 5-day bolus schedule."( Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.
Catalano, R; Comis, RL; DeLap, RJ; Grillo-Lopez, AJ; Hudes, GR; LaCreta, F, 1989
)
0.54
"The presence of low concentrations of the lipophilic dihydrofolate reductase inhibitors metoprine or trimetrexate, which cause little inhibition in the growth of cultured hepatoma cells in combination with weakly inhibiting concentrations of 5,10-dideazatetrahydrofolate, exhibit greater activity than would be predicted by the activity of the individual components."( Antifolate drug interactions: enhancement of growth inhibition due to the antipurine 5,10-dideazatetrahydrofolic acid by the lipophilic dihydrofolate reductase inhibitors metoprine and trimetrexate.
Boschelli, D; Galivan, J; Kerwar, SS; Nimec, Z; Oronsky, AL; Rhee, M, 1988
)
0.68
"This study evaluated the acute toxicity of trimetrexate (TMTX) used in combination with cyclosporine (CsA) for prevention of acute graft-versus-host disease (GVHD) in patients undergoing allogeneic marrow transplantation from HLA-mismatched, related donors."( A toxicity study of trimetrexate used in combination with cyclosporine as acute graft-versus-host disease prophylaxis in HLA-mismatched, related donor bone marrow transplants.
Anasetti, C; Beach, K; Deeg, HJ; Doney, KC; Hansen, JA; Martin, PJ; Nash, RA; Schubert, MM; Storb, R; Sullivan, KM, 1995
)
0.88
" Incubation of MCF-7 breast cells with 10 microM TMQ alone or in combination with 10 M 5-FU (TMQ 2 h prior to 5-FU [TMQ/5-FU] or 5-FU 2 h prior to TMQ[5-FU/TMQ]) resulted in similar inhibitory effects but dissimilar effects occurred in Hs 824."( Selectivity in human breast cancer and human bone marrow using trimetrexate in combination with 5-fluorouracil.
Bowen, D; Hawkins, M; Hughes, DE; Johnson, DH; Southerland, WM,
)
0.37
"The goal of the present report is to compare several published methods of analyzing drug-drug interaction data."( Comparison of methods for evaluating drug-drug interaction.
Au, JL; Wientjes, MG; Zhao, L, 2010
)
0.36
"The design and analysis of drug combination studies continue to be an area requiring further methodological developments."( Efficient experimental design and nonparametric modeling of drug interaction.
Fang, HB; Tan, M; Yu, T, 2010
)
0.36

Bioavailability

ExcerptReferenceRelevance
" With oral administration, the mean bioavailability was 44% (range, 19 to 67%)."( Bioavailability of oral trimetrexate in patients with acquired immunodeficiency syndrome.
Allegra, CJ; Balis, FM; Chabner, BA; Drake, JC; Lane, HC; Masur, H; Murphy, RF; Parrillo, JE; Poplack, DG; Rogers, P, 1988
)
0.58
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

No responses occurred in this population of patients with non-small-cell lung cancer. The most common adverse effect associated with trimetrexate is myelosuppression (neutropenia and thrombocytopenia) This is mitigated by coadministration of calcium folinate.

ExcerptRelevanceReference
" Forty-five rats of each sex were dosed intravenously with trimetrexate at 0, 1, 10, or 30 mg/kg (0, 6, 60, or 180 mg/m2), once daily for 5 consecutive days, followed by a 23-day recovery period."( Chronic toxicity of the anticancer agent trimetrexate in rats.
Dethloff, LA; Watkins, JR, 1992
)
0.79
" Pharmacokinetic data and clinical trials are reviewed, as well as adverse effects, drug interactions, and dosage guidelines."( Trimetrexate for Pneumocystis carinii pneumonia in patients with AIDS.
Amsden, GW; Kowalsky, SF; Morse, GD, 1992
)
1.73
" Although TMTX's pharmacokinetic parameters are variable, the need for plasma concentration monitoring at present is unclear, as no dose-response relationship has been established."( Trimetrexate for Pneumocystis carinii pneumonia in patients with AIDS.
Amsden, GW; Kowalsky, SF; Morse, GD, 1992
)
1.73
" Except for the testicular changes, these effects were most severe in animals dosed at 65 and 80 mg/kg in the oral x5 study (65-70% mortality)."( Toxicity of the anticancer folate antagonist trimetrexate in rats.
Graziano, MJ; Kim, SN; MacDonald, JR; Watkins, JR, 1992
)
0.54
" The dosage schedule was single-dose intravenous administration (single treatment), followed by one or two courses of 5-day intravenous administration (5-day treatment) at 3-week intervals."( [Phase I study of CI-898. CI-898 Study Group].
Ariyoshi, H; Furue, H; Hasegawa, K; Majima, H; Nakao, I; Niitani, H; Ohta, K; Taguchi, T; Tsukagoshi, S; Yasutomi, M, 1991
)
0.28
"To determine the maximal tolerable dosage of trimetrexate for treatment of pneumocystis pneumonia, 25 patients were treated each day with 45 mg/m2 of trimetrexate and 80 mg/m2 of leucovorin; 10 received 60 mg/m2 and 80 mg/m2; 12 received 60 mg/m2 and 160 mg/m2; and 6 received 90 mg/m2 and 160 mg/m2, respectively."( Trimetrexate-leucovorin dosage evaluation study for treatment of Pneumocystis carinii pneumonia.
Akil, B; Allegra, CJ; Feinberg, J; Hughlett, C; Lane, HC; Ogata-Arakaki, D; Sattler, FR; Shelhamer, J; Tuazon, CU; Verdegem, TD, 1990
)
1.98
" Consequently, the stability of the chemotherapeutic agents can influence the dosing accuracy and ultimately the achievement of the desired therapeutic goal."( Stability of trimetrexate, a new non-classical antifolate, in infusion solutions.
Ensminger, WD; Shukla, UA; Stetson, PL, 1989
)
0.65
" At the dosage and schedule of trimetrexate used, no responses occurred in this population of patients with non-small-cell lung cancer."( Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer.
Burke, MT; D'Acquisto, RW; Fanucchi, MP; Gralla, RJ; Heelan, RT; Kris, MG; Marks, LD, 1989
)
0.9
" The dosage chosen for the Phase 2 study, based only on the hematological dose limiting toxicity, was 10."( Trimetrexate and cyclophosphamide for metastatic inoperable nonsmall cell lung cancer.
Grove, W; Holsti, LR; Maasilta, P; Mattson, K; Tammilehto, L, 1988
)
1.72
" Courses were repeated at 3 week intervals with the trimetrexate dosage escalated according to patient tolerance."( Trimetrexate combined with cisplatin or etoposide in the treatment of non-small cell lung cancer: a pilot study.
Maroun, JA; Natale, RB; Robert, F, 1988
)
1.97
" The increases in the requirement of 5-methyltetrahydrofolate (5-methyl-THF) by the resistant sublines were more pronounced than PGA requirement, moving the dose-response curve nearly 3 log orders in magnitude to the right."( Folate requirements of methotrexate-resistant human acute lymphoblastic leukemia cell lines.
Holland, JF; Kano, Y; Ohnuma, T, 1986
)
0.27
" Dosage adjustment may have to be considered for patients who have renal dysfunction."( Clinical pharmacology of trimetrexate.
Covington, WP; Ho, DH; Krakoff, IH; Legha, SS; Newman, RA, 1987
)
0.58
" TMTX plasma levels were measured by HPLC every 3 days prior to daily dosing in patients receiving 4 mg/m2 to determine whether drug accumulation occurred during this prolonged administration schedule."( A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections.
Eisenhauer, E; Jolivet, J; Landry, L; McCormack, JJ; Pinard, MF; Tong, WP, 1987
)
0.6
" While TMQ appeared to be more immunosuppressive than MTX following in vitro addition of the drugs, the converse appeared to be true when dosing was performed in vivo."( Comparative effects on the immune system of methotrexate and trimetrexate.
Ackermann, MF; Germolec, DR; Lamm, KR; Luster, MI; Rosenthal, GJ, 1987
)
0.51
" The most common adverse effect associated with trimetrexate is myelosuppression (neutropenia and thrombocytopenia); this is mitigated by coadministration of calcium folinate and is generally reversible upon dosage reduction or discontinuation."( Trimetrexate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of Pneumocystis carinii pneumonia.
Fulton, B; McTavish, D; Wagstaff, AJ, 1995
)
1.99
" Initial dosage reductions in patients with liver disease and/or low protein concentrations may be necessary since TMTX is significantly protein bound and cleared primarily by hepatic metabolism."( A phase I trial of trimetrexate (NSC352122) on a daily x 5 schedule in patients with refractory adult leukemia.
Balis, FM; Brown, TD; Craig, JB; Denham, CA; Havlin, K; Kuhn, JG; Rodriguez, G; Von Hoff, DD, 1993
)
0.61
" Serial blood samples were obtained over 24 hours after dosing and analyzed for trimetrexate, dapsone, and monoacetyldapsone, and pharmacokinetic parameters were determined."( Pharmacokinetics of trimetrexate and dapsone in AIDS patients with Pneumocystis carinii pneumonia.
Chatterjee, DJ; Dubé, MP; Koda, RT; Li, WY; Sattler, FR; Stansell, JD, 1999
)
0.85
"The P & T Committee at Trinity Lutheran Hospital, a 320-bed, community/teaching hospital in Kansas City, MO, has developed dosing and monitoring guidelines for foscarnet sodium (Foscavir) and trimetrexate glucuronate (Neutrexin)--two drugs used to treat patients with opportunistic infections associated with the human immunodeficiency virus (HIV)."( Dosing guidelines for foscarnet and trimetrexate.
Chase, K; Henry, RB; O'Connor, MC; Wooten, JM, 1995
)
0.76
" The dosage of TMTX was reduced to 8 mg/m(2) daily for 5 days for those who had received prior radiotherapy."( Phase II trial of trimetrexate for patients with advanced gastric carcinoma: an Eastern Cooperative Oncology Group study (E1287).
Asbury, RF; Greenberg, BR; Haller, DG; Lipsitz, S; Qazi, R; Ramanathan, RK, 1999
)
0.64
" The base model employed for modeling dose-response effect is the four parameter Hill equation [1]."( A new nonlinear mixture response surface paradigm for the study of synergism: a three drug example.
Brun, Y; Greco, WR; Slocum, HK; White, DB; Wrzosek, C, 2003
)
0.32
" Eight episodes of grade II or III stomatitis were observed and were responsible for dosage modifications of TMTX and 5-FU."( Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma.
Bologna, F; Dominguez, ME; Lacava, JA; Leone, BA; Machiavelli, MR; Ortiz, EH; Pérez, JE; Romero, AO; Salum, G; Vallejo, CT, 2004
)
0.59
" "Strong nonlinear blending" is a novel concept that provides a flexible paradigm for the assessment of combination drug synergy that is applicable to any shaped combination-drug dose-response surface; issues of varying relative potency, partial inhibitors, potentiation, or coalism pose no problems at all."( A review of synergy concepts of nonlinear blending and dose-reduction profiles.
Peterson, JJ, 2010
)
0.36
" Further clinical evaluation is warranted to investigate whether a low dosage of these antifolates can elicit immunosuppressive effects equivalent to MTX, and whether they are superior to MTX in patients who fail to respond to MTX."( Methotrexate analogues display enhanced inhibition of TNF-α production in whole blood from RA patients.
Assaraf, YG; Dijkmans, BA; Gerards, AH; Jansen, G; Lems, WF; Oerlemans, R; Scheper, RJ; van der Heijden, JW, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (33)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency39.81070.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency12.58930.004023.8416100.0000AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency5.61010.140911.194039.8107AID2451
phosphopantetheinyl transferaseBacillus subtilisPotency39.67710.141337.9142100.0000AID1490; AID2701
Fumarate hydrataseHomo sapiens (human)Potency37.22120.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency44.66840.031637.5844354.8130AID504865
PPM1D proteinHomo sapiens (human)Potency26.21230.00529.466132.9993AID1347411
Microtubule-associated protein tauHomo sapiens (human)Potency29.88160.180013.557439.8107AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency44.66840.011212.4002100.0000AID1030
EWS/FLI fusion proteinHomo sapiens (human)Potency1.57620.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
polyproteinZika virusPotency37.22120.00308.794948.0869AID1347053
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency10.00000.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency17.78280.540617.639296.1227AID2528
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency28.18380.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency17.01570.354828.065989.1251AID504847
DNA polymerase kappa isoform 1Homo sapiens (human)Potency25.11890.031622.3146100.0000AID588579
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.47780.005612.367736.1254AID624032; AID624044
Interferon betaHomo sapiens (human)Potency26.21230.00339.158239.8107AID1347411
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydrofolate reductase Mycobacterium aviumIC50 (µMol)0.30120.00060.17161.5000AID291236; AID457190; AID56938; AID57610; AID58090
Dihydrofolate reductaseHomo sapiens (human)IC50 (µMol)24.30490.00060.87267.3000AID1591492; AID1623967; AID1797714; AID488383; AID56807; AID56959; AID56963; AID56964; AID56983; AID56984; AID747614
Dihydrofolate reductaseHomo sapiens (human)Ki0.02440.00000.37564.9000AID1915711; AID219255; AID57133; AID57140
Dihydrofolate reductaseMus musculus (house mouse)Ki0.00040.00000.21713.9000AID141370; AID219257
Dihydrofolate reductaseLacticaseibacillus caseiIC50 (µMol)0.14350.00130.26964.9000AID57603; AID57753
Dihydrofolate reductaseSaccharomyces cerevisiae S288CIC50 (µMol)0.04200.03100.03650.0420AID55696
Dihydrofolate reductaseEscherichia coli K-12IC50 (µMol)0.17980.00150.55126.8000AID1797714; AID55714; AID55859; AID56347; AID57239; AID57240; AID57592; AID57630
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)0.02600.00040.908610.0000AID55694; AID55859
Dihydrofolate reductasePneumocystis cariniiIC50 (µMol)1.17200.00060.54766.2000AID1797714; AID291232; AID341473; AID390567; AID457202; AID55687; AID55689; AID55694; AID55698; AID55699; AID55701; AID55702; AID55703; AID55705; AID55820; AID55821; AID55827; AID55830; AID55831; AID55832; AID55833; AID55836; AID55838; AID55839; AID55840; AID55841; AID55844; AID55846; AID55855; AID55858; AID55989; AID56939; AID57626; AID747610
Dihydrofolate reductasePneumocystis cariniiKi0.00070.00000.04680.1520AID55851
Dihydrofolate reductaseCandida albicansIC50 (µMol)0.04000.00220.91875.0000AID57074
Dihydrofolate reductaseCandida albicansKi0.00190.00190.00190.0019AID57076
Dipeptidyl peptidase 4Homo sapiens (human)IC50 (µMol)0.01000.00010.444410.0000AID56182
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)IC50 (µMol)0.00800.00040.615610.0000AID57971
Bifunctional dihydrofolate reductase-thymidylate synthaseToxoplasma gondiiIC50 (µMol)0.57880.00061.042810.0000AID1623966; AID1797714; AID291235; AID390571; AID457208; AID55712; AID56165; AID56167; AID56169; AID56171; AID56172; AID56174; AID56175; AID56176; AID56178; AID56179; AID56180; AID56182; AID56183; AID56184; AID56187; AID56189; AID56310; AID56312; AID56314; AID56315; AID56317; AID56318; AID56319; AID56321; AID56324; AID56325; AID56329; AID56333; AID56345; AID57066
Bifunctional dihydrofolate reductase-thymidylate synthaseTrypanosoma cruziIC50 (µMol)0.02020.02020.06510.1100AID488382
Bifunctional dihydrofolate reductase-thymidylate synthaseTrypanosoma cruziKi0.00660.00660.00660.0066AID488382
Dihydrofolate reductaseRattus norvegicus (Norway rat)IC50 (µMol)0.07940.00060.35076.2000AID1797714; AID291237; AID341476; AID390569; AID457205; AID57069; AID57797; AID57798; AID57799; AID57809; AID57811; AID57813; AID57819; AID57820; AID57822; AID57826; AID57960; AID57961; AID57965; AID57966; AID57968; AID57969; AID57970; AID57971; AID57972; AID57977; AID57978; AID57979; AID57982; AID57984; AID57985; AID57988; AID57990; AID57993; AID747611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (65)

Processvia Protein(s)Taxonomy
tetrahydrobiopterin biosynthetic processDihydrofolate reductaseHomo sapiens (human)
one-carbon metabolic processDihydrofolate reductaseHomo sapiens (human)
negative regulation of translationDihydrofolate reductaseHomo sapiens (human)
axon regenerationDihydrofolate reductaseHomo sapiens (human)
response to methotrexateDihydrofolate reductaseHomo sapiens (human)
dihydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate biosynthetic processDihydrofolate reductaseHomo sapiens (human)
folic acid metabolic processDihydrofolate reductaseHomo sapiens (human)
positive regulation of nitric-oxide synthase activityDihydrofolate reductaseHomo sapiens (human)
regulation of removal of superoxide radicalsDihydrofolate reductaseHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
10-formyltetrahydrofolate biosynthetic processDihydrofolate reductaseEscherichia coli K-12
response to xenobiotic stimulusDihydrofolate reductaseEscherichia coli K-12
folic acid biosynthetic processDihydrofolate reductaseEscherichia coli K-12
one-carbon metabolic processDihydrofolate reductaseEscherichia coli K-12
response to methotrexateDihydrofolate reductaseEscherichia coli K-12
tetrahydrofolate biosynthetic processDihydrofolate reductaseEscherichia coli K-12
response to antibioticDihydrofolate reductaseEscherichia coli K-12
dihydrofolate metabolic processDihydrofolate reductaseEscherichia coli K-12
folic acid metabolic processDihydrofolate reductaseEscherichia coli K-12
behavioral fear responseDipeptidyl peptidase 4Homo sapiens (human)
response to hypoxiaDipeptidyl peptidase 4Homo sapiens (human)
proteolysisDipeptidyl peptidase 4Homo sapiens (human)
cell adhesionDipeptidyl peptidase 4Homo sapiens (human)
positive regulation of cell population proliferationDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of extracellular matrix disassemblyDipeptidyl peptidase 4Homo sapiens (human)
peptide hormone processingDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellDipeptidyl peptidase 4Homo sapiens (human)
T cell costimulationDipeptidyl peptidase 4Homo sapiens (human)
regulation of cell-cell adhesion mediated by integrinDipeptidyl peptidase 4Homo sapiens (human)
locomotory exploration behaviorDipeptidyl peptidase 4Homo sapiens (human)
psychomotor behaviorDipeptidyl peptidase 4Homo sapiens (human)
T cell activationDipeptidyl peptidase 4Homo sapiens (human)
endothelial cell migrationDipeptidyl peptidase 4Homo sapiens (human)
symbiont entry into host cellDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated virion attachment to host cellDipeptidyl peptidase 4Homo sapiens (human)
negative chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
membrane fusionDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of neutrophil chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
glucagon processingDipeptidyl peptidase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (26)

Processvia Protein(s)Taxonomy
mRNA regulatory element binding translation repressor activityDihydrofolate reductaseHomo sapiens (human)
mRNA bindingDihydrofolate reductaseHomo sapiens (human)
dihydrofolate reductase activityDihydrofolate reductaseHomo sapiens (human)
folic acid bindingDihydrofolate reductaseHomo sapiens (human)
NADPH bindingDihydrofolate reductaseHomo sapiens (human)
sequence-specific mRNA bindingDihydrofolate reductaseHomo sapiens (human)
NADP bindingDihydrofolate reductaseHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
dihydrofolate reductase activityDihydrofolate reductaseEscherichia coli K-12
protein bindingDihydrofolate reductaseEscherichia coli K-12
folic acid bindingDihydrofolate reductaseEscherichia coli K-12
oxidoreductase activityDihydrofolate reductaseEscherichia coli K-12
NADP bindingDihydrofolate reductaseEscherichia coli K-12
methotrexate bindingDihydrofolate reductaseEscherichia coli K-12
dihydrofolic acid bindingDihydrofolate reductaseEscherichia coli K-12
NADP+ bindingDihydrofolate reductaseEscherichia coli K-12
NADPH bindingDihydrofolate reductaseEscherichia coli K-12
virus receptor activityDipeptidyl peptidase 4Homo sapiens (human)
protease bindingDipeptidyl peptidase 4Homo sapiens (human)
aminopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
serine-type endopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
signaling receptor bindingDipeptidyl peptidase 4Homo sapiens (human)
protein bindingDipeptidyl peptidase 4Homo sapiens (human)
serine-type peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
dipeptidyl-peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
identical protein bindingDipeptidyl peptidase 4Homo sapiens (human)
protein homodimerization activityDipeptidyl peptidase 4Homo sapiens (human)
chemorepellent activityDipeptidyl peptidase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytosolDihydrofolate reductaseHomo sapiens (human)
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytosolDihydrofolate reductaseMus musculus (house mouse)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
cytosolDihydrofolate reductaseEscherichia coli K-12
cytosolDihydrofolate reductaseEscherichia coli K-12
extracellular regionDipeptidyl peptidase 4Homo sapiens (human)
lysosomal membraneDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
focal adhesionDipeptidyl peptidase 4Homo sapiens (human)
cell surfaceDipeptidyl peptidase 4Homo sapiens (human)
membraneDipeptidyl peptidase 4Homo sapiens (human)
apical plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
lamellipodiumDipeptidyl peptidase 4Homo sapiens (human)
endocytic vesicleDipeptidyl peptidase 4Homo sapiens (human)
lamellipodium membraneDipeptidyl peptidase 4Homo sapiens (human)
membrane raftDipeptidyl peptidase 4Homo sapiens (human)
intercellular canaliculusDipeptidyl peptidase 4Homo sapiens (human)
extracellular exosomeDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (386)

Assay IDTitleYearJournalArticle
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID56319Inhibitory concentration against Dihydrofolate reductase from Toxoplasma gondii (tg)1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Synthesis and dihydrofolate reductase inhibitory activities of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates.
AID457202Inhibition of Pneumocystis carinii DHFR at 37 degC by spectrophotometry2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID55833Inhibitory activity against Pneumocystis carinii dihydrofolate reductase1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
AID161597Inhibition of 0.5-0.7 uM of U-46,619 induced human platelet aggregation1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and thromboxane A2 antagonist activity of N-benzyltrimetoquinol analogues.
AID1123093Inhibition of dihydrofolate reductase in human acute lymphocytic leukemia cells1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Multivariate analysis and quantitative structure-activity relationships. Inhibition of dihydrofolate reductase and thymidylate synthetase by quinazolines.
AID1123094Inhibition of dihydrofolate reductase in mouse L1210R cells1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Multivariate analysis and quantitative structure-activity relationships. Inhibition of dihydrofolate reductase and thymidylate synthetase by quinazolines.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID57753Inhibitory activity against Dihydrofolate reductase from Lactobacillus casei (lcDHFR)1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
AID55832Inhibitory activity against Pneumocystis carinii Dihydrofolate reductase1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID291237Inhibition of rat liver DHFR2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as antifolates.
AID56317Inhibitory activity against Toxoplasma gondii Dihydrofolate reductase1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID55944Cytotoxic activity was evaluated against Daoy tumor cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID235660Selectivity index was determined by the ratio for IC50 of rat liver DHFR to the IC50 of Pneumocystis carinii DHFR; Range: 0.11-0.272004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
AID457205Inhibition of rat liver DHFR at 37 degC by spectrophotometry2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID341473Inhibition of Pneumocystis carinii DHFR using dihydrofolic acid substrate and NADPH cofactor2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
AID56184Inhibitory activity against Dihydrofolate reductase from Toxoplasma gondii (tgDHFR)1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
AID291232Inhibition of Pneumocystis carinii DHFR2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as antifolates.
AID57820Inhibitory activity against Dihydrofolate reductase from rat liver1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
6-substituted 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
AID210620Inhibitory activity against Toxoplasma gondii cell growth(ca denotes calculated value)1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
AID89407Inhibition of 0.5-0.7 uM of U-46,619 induced [14C]5-HT secretion1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and thromboxane A2 antagonist activity of N-benzyltrimetoquinol analogues.
AID57630Inhibition of dihydrofolate reductase from pneumocystis carinii.2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
AID1623967Inhibition of human DHFR expressed in Escherichia coli BL21 competent cells using DHF as substrate preincubated for 15 mins followed by substrate and NADPH addition and measured after 60 mins by resazurin dye based diaphorase-coupled assay2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
AID747610Inhibition of Pneumocystis carinii DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID362422Antiproliferative activity against human RFC expressing Chinese hamster R2 cells2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID488382Inhibition of Trypanosoma cruzi DHFR by spectrophotometric assay2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Synthesis and characterization of potent inhibitors of Trypanosoma cruzi dihydrofolate reductase.
AID200586Tested for inhibitory concentration against SCC-VII murine squamous carcinoma cell line1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
AID94508Cytotoxic activity was evaluated against KBV-1 cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID58148Ratio of inhibition of dihydrofolate reductase(DHFR) from rat(rl) liver and Pneumocystis carinii(pc)1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
AID559548Antimalarial activity against pyrimethamine-sensitive Plasmodium falciparum 3D7 expressing wild type DHFR by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation.
AID291240Selectivity ratio of IC50 for rat liver DHFR to IC50 for Mycobacterium avium DHFR2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as antifolates.
AID56347Inhibition of dihydrofolate reductase in Toxoplasma gondii.1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID235728Selectivity ratio (IC50rlDHFR)/(IC50 tgDHFR)2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.
AID57603Inhibitory activity against Dihydrofolate reductase from Lactobacillus casei1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
6-substituted 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
AID247430Growth inhibitory activity against human HCT116 cell line in presence of Hypoxanthine thymidine(HT)2004Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16
Structural studies on bioactive compounds. 39. Biological consequences of the structural modification of DHFR-inhibitory 2,4-diamino-6-(4-substituted benzylamino-3-nitrophenyl)-6-ethylpyrimidines ('benzoprims').
AID101911Cytotoxic activity was evaluated against MCF-7/ADR cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID57985Inhibition of Dihydrofolate reductase of rat liver1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases.
AID291235Inhibition of Toxoplasma gondii DHFR2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as antifolates.
AID227228Selectivity ratio measured as the IC50 ratio of rlDHFR to the IC50 tgDHFR.1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Synthesis and biological activities of conformationally restricted, tricyclic nonclassical antifolates as inhibitors of dihydrofolate reductases.
AID56174Compound was tested for inhibition activity against Toxoplasma gondii (Toxoplasma gondii) Dihydrofolate reductase1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID341477Selectivity for Pneumocystis carinii DHFR over rat liver DHFR2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
AID197535Inhibition of U-46,619-induced contraction of Rat thoracic aorta expressed as pKB value of the compound1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and thromboxane A2 antagonist activity of N-benzyltrimetoquinol analogues.
AID55705Inhibition of Dihydrofolate reductase of Pneumocystis carinii1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID57240Inhibitory activity against recombinant Escherichia coli dihydrofolate reductase2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
AID55846Inhibitory activity against purified dihydrofolate reductase from Pneumocystis carinii.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Nonclassical 2,4-diamino-6-(aminomethyl)-5,6,7,8-tetrahydroquinazoline antifolates: synthesis and biological activities.
AID233286Relative binding affinity to rat liver and Toxoplasma gondii DHFR.1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
AID55581Cytotoxic Activity was evaluated against D54 tumor cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID57814Inhibition against Dihydrofolate reductase in rat liver1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Effect of N9-methylation and bridge atom variation on the activity of 5-substituted 2,4-diaminopyrrolo[2,3-d]pyrimidines against dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID1591495Selectivity ratio of IC50 for inhibition of recombinant human DHFR using 18 uM DHFA as substrate to IC50 for inhibition of Pneumocystis jirovecii DHFR using 18 uM DHFA as substrate2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection.
AID55703Inhibition against Dihydrofolate reductase in Pneumocystis carinii1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Effect of N9-methylation and bridge atom variation on the activity of 5-substituted 2,4-diaminopyrrolo[2,3-d]pyrimidines against dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID55701Inhibition of Pneumocystis carinii dihydrofolate reductase1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
AID747611Inhibition of rat liver DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID233409Ratio of IC50 evaluated towards DHFR of rat liver to Pneumocystis carinii1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Nonclassical 2,4-diamino-6-(aminomethyl)-5,6,7,8-tetrahydroquinazoline antifolates: synthesis and biological activities.
AID57965Inhibitory activity against Dihydrofolate reductase from rat liver was evaluated using 90 uM dihydrofolic acid as substrate1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
AID233412Selectivity ratio is defined as IC50 rlDHFR/IC50 tgDHFR1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases.
AID48772Minimum inhibitory concentration evaluated against Candida albicans1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID747609Selectivity ratio of IC50 for rat liver DHFR to IC50 for Mycobacterium avium DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID390570Selectivity ratio, IC50 for rat liver dihydrofolate reductase to IC50 for Pneumocystis carinii dihydrofolate reductase2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
N9-substituted 2,4-diaminoquinazolines: synthesis and biological evaluation of lipophilic inhibitors of pneumocystis carinii and toxoplasma gondii dihydrofolate reductase.
AID56963Inhibitory activity against recombinant human Dihydrofolate reductase2002Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23
Synthesis of classical and nonclassical, partially restricted, linear, tricyclic 5-deaza antifolates.
AID214392Cytotoxic activity was evaluated against U373MG tumor cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID233114Ratio of IC50 against rat liver DHFR and Pneumocystis carinii DHFR (IC50rl/IC50pc)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Novel 2,4-diamino-5-substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductases.
AID233406Ratio for IC50 of mammalian DHFR to IC50 of Pneumocystis carinii DHFR1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
AID55844Inhibition of dihydrofolate reductase (DHFR) from Pneumocystis carinii(pc)1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
AID55714Inhibition of dihydrofolate reductase from Toxoplasma gondii.2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
AID8659Cytotoxic activity evaluated against A549 tumor cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID154146Cytotoxic activity was evaluated against P388D1/ADR cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID56167Inhibition of Toxoplasma gondii (tc) Dihydrofolate reductase1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Novel 2,4-diamino-5-substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductases.
AID101913Cytotoxic Activity was evaluated against MCF-7 cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID1623968Selectivity ratio of IC50 for human DHFR to IC50 for Toxoplasma gondii DHFR-TS2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
AID55851Binding affinity was reported with purified recombinant Pneumocystis carinii Dihydrofolate reductase1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
AID56187Inhibitory activity against Toxoplasma gondii dihydrofolate reductase2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
AID234735Selectivity ratio of IC50 value against rat liver DHFR and Toxoplasma gondii DHFR1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID57968Inhibitory activity against rat liver dihydrofolate reductase1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
AID291238Selectivity ratio of IC50 for rat liver DHFR to IC50 for Pneumocystis carinii DHFR2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as antifolates.
AID1591492Inhibition of recombinant human DHFR assessed as reduction in consumption of NADPH using 18 uM DHFA as substrate2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection.
AID57239Inhibitory activity against recombinant Dihydrofolate reductase from Escherichia coli (ecDHFR)1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID57969Inhibitory activity against rat liver dihydrofolate reductase.1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii.
AID57988Inhibition of rat liver dihydrofolate reductase.1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID57799Concentration inhibiting rat liver dihydrofolate reductase. 1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
2,4-Diaminopyrido[3,2-d]pyrimidine inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii.
AID55855Inhibitory activity against Pneumocystis carinii dihydrofolate reductase (in 90 uM dihydrofolic acid)1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases.
AID232059Selectivity index was determined as ratio of IC50 against rat DHFR to that of IC50 against Mycobacterium avium DHFR2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium.
AID235849Selectivity ratio is the ratio between the IC50 values of rat liver and Pneumocystis carinii1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID55831Inhibitory activity against DHFR (Dihydrofolate reductase) from Pneumocystis carinii.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Structure-based design of selective inhibitors of dihydrofolate reductase: synthesis and antiparasitic activity of 2, 4-diaminopteridine analogues with a bridged diarylamine side chain.
AID341479Selectivity for Mycobacterium avium DHFR over rat liver DHFR2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID216019Cytotoxic Activity was evaluated against Vero tumor cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID56180Inhibition against Dihydrofolate reductase in Toxoplasma gondii1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Effect of N9-methylation and bridge atom variation on the activity of 5-substituted 2,4-diaminopyrrolo[2,3-d]pyrimidines against dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID23271Partition coefficient (logD7.4)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID559549Antimalarial activity against Plasmodium falciparum Kenyan isolates by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID56182Inhibition of Dihydrofolate reductase of Toxoplasma gondii1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity.
AID56310Inhibitory activity against dihydrofolate reductase (DHFR) from Toxoplasma gondii1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents.
AID457209Selectivity ratio of IC50 for rat liver DHFR to IC50 for Toxoplasma gondii DHFR2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID56314Inhibitory activity against Dihydrofolate reductase from Toxoplasma gondii was evaluated using 90 uM dihydrofolic acid as substrate1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
AID197329Inhibition of U-46,619-induced contraction of Rat thoracic aorta in the presence of indomethacin, at conc 100 uM1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and thromboxane A2 antagonist activity of N-benzyltrimetoquinol analogues.
AID57819Inhibition of Dihydrofolate reductase (DHFR) of in rat liver1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity.
AID57822Inhibitory activity against Dihydrofolate reductase from rat liver (rlDHFR)1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
AID488384Selectivity ratio of IC50 for human DHFR to IC50 for Trypanosoma cruzi DHFR2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Synthesis and characterization of potent inhibitors of Trypanosoma cruzi dihydrofolate reductase.
AID560258Antimalarial activity against Plasmodium falciparum isolate Kil-164 expressing DHFR Ser108Asn, Asn51Ile, Cys59Arg and Ile164Leu quadruple mutant by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation.
AID141370Inhibitory constant for F31A/F34A murine dihydrofolate reductase (DHFR)2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Dihydrofolate reductase mutant with exceptional resistance to methotrexate but not to trimetrexate.
AID235861IC50(rlDHFR)/IC50(pcDHFR) Ratio of the compound2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii.
AID232759Selectivity index measured as the ratio of IC50 for rat liver DHFR to IC50 for Pneumocystis carinii DHFR.1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structural studies on bioactive compounds. 28. Selective activity of triazenyl-substituted pyrimethamine derivatives against Pneumocystis carinii dihydrofolate reductase.
AID57960Inhibition of dihydrofolate reductase from rat liver.2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
AID55694Inhibitory activity against pneumocystis carinii Dihydrofolate reductase2002Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23
Synthesis of classical and nonclassical, partially restricted, linear, tricyclic 5-deaza antifolates.
AID55989Inhibitory activity against dihydrofolate reductase from pneumocystis carinii1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
AID55820Inhibitory activity against Dihydrofolate reductase from Pneumocystis carinii1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
6-substituted 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID57982Inhibition of rat liver dihydrofolate reductase1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Synthesis of 5-methyl-5-deaza nonclassical antifolates as inhibitors of dihydrofolate reductases and as potential antipneumocystis, antitoxoplasma, and antitumor agents.
AID291236Inhibition of Mycobacterium avium DHFR2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as antifolates.
AID1915711Inhibition of DHFR (unknown origin) assessed as inhibition constant2021European journal of medicinal chemistry, Feb-05, Volume: 211Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
AID232061Selectivity index was determined as ratio of IC50 against rat DHFR to that of IC50 against Toxoplasma gondii DHFR2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium.
AID233680Selectivity ratio of rat liver(rl) / Pneumocystis carinii (pc)1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Synthesis and dihydrofolate reductase inhibitory activities of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID362428Antiproliferative activity against human RFC and FRalpha expressing human KB cells in presence of folic acid2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID291239Selectivity ratio of IC50 for rat liver DHFR to IC50 for Toxoplasma gondii DHFR2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as antifolates.
AID234733Selectivity ratio of IC50 value against rat liver DHFR to that of Pneumocystis carinii DHFR1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID247221Growth inhibitory activity against human HT-29 cell line2004Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16
Structural studies on bioactive compounds. 39. Biological consequences of the structural modification of DHFR-inhibitory 2,4-diamino-6-(4-substituted benzylamino-3-nitrophenyl)-6-ethylpyrimidines ('benzoprims').
AID57993Inhibitory activity against purified dihydrofolate reductase from rat1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Nonclassical 2,4-diamino-6-(aminomethyl)-5,6,7,8-tetrahydroquinazoline antifolates: synthesis and biological activities.
AID235671Selectivity index was determined by the ratio for IC50 of rat liver DHFR to the IC50 of Toxoplasma gondii DHFR; Range: 0.23-1.22004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
AID57977Inhibitory concentration against Dihydrofolate reductase from Rat liver (rl)1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Synthesis and dihydrofolate reductase inhibitory activities of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID100631Anti tumor activity against L1210 leukemia in tissue culture and the molar concentration required to reduce the number of L1210 cells1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antimalarial and antitumor effects of 2-amino-4-(hydrazino and hydroxyamino)-6-[(aryl)thio]quinazolines.
AID57979Inhibitory concentration against dihydrofolate reductase DHFR from rat liver.2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii.
AID233637Ratio of inhibitory concentration of rat liver and Toxoplasma gondii DHFR1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii.
AID55841Inhibitory concentration against dihydrofolate reductase dihydrofolate reductase from Pneumocystis carinii.2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii.
AID56171Inhibitory activity against Toxoplasma gondii (tg) Dihydrofolate reductase (DHFR)2002Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23
Synthesis of classical and nonclassical, partially restricted, linear, tricyclic 5-deaza antifolates.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID235727Selectivity ratio (IC50 rlDHFR)/(IC50 maDHFR)2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.
AID56315Inhibitory activity against DHFR (Dihydrofolate reductase) from Toxoplasma gondii.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Structure-based design of selective inhibitors of dihydrofolate reductase: synthesis and antiparasitic activity of 2, 4-diaminopteridine analogues with a bridged diarylamine side chain.
AID94507Cytotoxic activity was evaluated against KBV-1 cells in presence of reserpine1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID57971Inhibitory activity against rat dihydrofolate reductase2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium.
AID57978Inhibitory concentration against Rat liver Dihydrofolate reductase1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Synthesis and biological activities of conformationally restricted, tricyclic nonclassical antifolates as inhibitors of dihydrofolate reductases.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID457210Selectivity ratio of IC50 for rat liver DHFR to IC50 for Mycobacterium avium DHFR2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID390567Inhibition of Pneumocystis carinii dihydrofolate reductase2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
N9-substituted 2,4-diaminoquinazolines: synthesis and biological evaluation of lipophilic inhibitors of pneumocystis carinii and toxoplasma gondii dihydrofolate reductase.
AID58090Inhibitory concentration against Mycobacterium avium dihydrofolate reductase2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium.
AID56807In vitro inhibition of human dihydrofolate reductase1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Selective inhibitors of Candida albicans dihydrofolate reductase: activity and selectivity of 5-(arylthio)-2,4-diaminoquinazolines.
AID233410Ratio of IC50 evaluated towards DHFR of rat liver to Toxoplasma gondii1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Nonclassical 2,4-diamino-6-(aminomethyl)-5,6,7,8-tetrahydroquinazoline antifolates: synthesis and biological activities.
AID233115Ratio of the IC50 against rat liver DHFR and Toxoplasma gondii DHFR (IC50rl/IC50tg)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Novel 2,4-diamino-5-substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductases.
AID56324Inhibitory concentration against Toxoplasma gondii dihydrofolate reductase2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium.
AID229443Selectivity ratio as the ratio of IC50 value against recombinant human (rh) DHFR to that of Escherichia coli (ec) DHFR.2002Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23
Synthesis of classical and nonclassical, partially restricted, linear, tricyclic 5-deaza antifolates.
AID56179Inhibitory concentration against Toxoplasma gondii dihydrofolate reductase1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structural studies on bioactive compounds. 28. Selective activity of triazenyl-substituted pyrimethamine derivatives against Pneumocystis carinii dihydrofolate reductase.
AID747613Inhibition of Pneumocystis jirovecii recombinant DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID55840Inhibitory concentration against Pneumocystis carinii dihydrofolate reductase2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium.
AID56318Inhibitory activity against Toxoplasma gondii dihydrofolate reductase1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID56312Inhibition of recombinant Dihydrofolate reductase from Toxoplasma gondii (tgDHFR)1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
AID55827Inhibitory activity against dihydrofolate reductase (DHFR) from Pneumocystis carinii1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents.
AID55859Inhibition of dihydrofolate reductase in pneumocystis carinii.1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID154143Cytotoxic activity was evaluated against P388D1 tumor cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID56959Inhibitory activity against Dihydrofolate reductase from recombinant human (hDHFR)1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
AID56169Inhibition of dihydrofolate reductase (DHFR) from Toxoplasma gondii(tg)1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
AID341476Inhibition of rat liver DHFR using dihydrofolic acid substrate and NADPH cofactor2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
AID390572Selectivity ratio, IC50 for rat liver dihydrofolate reductase to IC50 for Toxoplasma gondii dihydrofolate reductase2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
N9-substituted 2,4-diaminoquinazolines: synthesis and biological evaluation of lipophilic inhibitors of pneumocystis carinii and toxoplasma gondii dihydrofolate reductase.
AID200581Tested for inhibitory concentration against human SCC25 cell line1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
AID56964Inhibitory activity against human dihydrofolate reductase2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
AID747607Selectivity ratio of IC50 for rat liver DHFR to IC50 for Pneumocystis carinii DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID233411Selectivity ratio is defined as IC50 rlDHFR/IC50 pcDHFR1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases.
AID235851Selectivity ratio is the ratio between the IC50 values of rat liver and Toxoplasma gondii1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID141371Inhibitory constant for F31A/F34A murine dihydrofolate reductase (DHFR)2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Dihydrofolate reductase mutant with exceptional resistance to methotrexate but not to trimetrexate.
AID57140Inhibitory activity against Leu22-Phe mutant human Dihydrofolate reductase1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID457190Inhibition of Mycobacterium avium DHFR at 37 degC by spectrophotometry2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID57990Inhibition of dihydrofolate reductase (DHFR) from rat liver (rl)1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
AID362424Antiproliferative activity against human FRalpha expressing Chinese hamster RT16 cells in presence of folic acid2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID55712Concentration required to inhibit the Toxoplasma gondii Dihydrofolate reductase by 50% was determined; Range: 8-302004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
AID57133Inhibition of human recombinant Dihydrofolate reductase enzyme1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID56345Inhibitory activity against Toxoplasma gondii dihydrofolate reductase (in 90 uM dihydrofolic acid)1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID247429Growth inhibitory activity against human HT-29 cell line in presence of Hypoxanthine thymidine(HT)2004Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16
Structural studies on bioactive compounds. 39. Biological consequences of the structural modification of DHFR-inhibitory 2,4-diamino-6-(4-substituted benzylamino-3-nitrophenyl)-6-ethylpyrimidines ('benzoprims').
AID95763Inhibitory concentration against Lactobacillus casei1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Synthesis of 5-methyl-5-deaza nonclassical antifolates as inhibitors of dihydrofolate reductases and as potential antipneumocystis, antitoxoplasma, and antitumor agents.
AID57970Inhibitory activity against rat liver dihydrofolate reductase (in 90 uM dihydrofolic acid)1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases.
AID235729Selectivity ratio [(IC50 rlDHFR)/(IC50 pcDHFR)2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID20863Relative concentration of compound in brain compared to concentration in plasma (9.4 ug/mL) at the time of tissue collection from mice; relative concentration1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID57809Concentration required to inhibit the rat liver Dihydrofolate reductase by 50% was determined; Range: 7.0-9.22004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
AID390571Inhibition of Toxoplasma gondii dihydrofolate reductase2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
N9-substituted 2,4-diaminoquinazolines: synthesis and biological evaluation of lipophilic inhibitors of pneumocystis carinii and toxoplasma gondii dihydrofolate reductase.
AID100309Cross resistance to the compound expressed as log of ratio of molar concentration of drug inducing 50% inhibition of growth in murine leukemia L1210/R71 and L1210/0 cells1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID233138Selectivity for dihydrofolate reductase enzyme in rat liver and Pneumocystis carinii1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases.
AID56165Inhibition of Toxoplasma gondii dihydrofolate reductase1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Synthesis of 5-methyl-5-deaza nonclassical antifolates as inhibitors of dihydrofolate reductases and as potential antipneumocystis, antitoxoplasma, and antitumor agents.
AID55838Inhibitory concentration against Dihydrofolate reductase from Pneumocystis carinii (pc)1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Synthesis and dihydrofolate reductase inhibitory activities of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates.
AID235862IC50(rlDHFR)/IC50(tgDHFR) Ratio of the compound2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii.
AID560257Antimalarial activity against Plasmodium falciparum Kenyan isolates expressing DHFR Ser108Asn, Asn51Ile and Cys59Arg triple mutant by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation.
AID56938Inhibitory concentration against Dihydrofolate reductase from Mycobacterium avium (Mycobacterium avium)2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.
AID141369Combined effect of active site mutation F31A and F34A on inhibitory effect for F31A/F34A murine dihydrofolate reductase (DHFR)2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Dihydrofolate reductase mutant with exceptional resistance to methotrexate but not to trimetrexate.
AID235734Selectivity ratio between the IC50 values of DHFR from rat liver and DHFR from Toxoplasma gondii1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
AID57972Inhibitory activity against rat liver Dihydrofolate reductase1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID233287Selectivity ratio is IC50 of rat liver DHFR to that of Toxoplasma gondii DHFR1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
AID231131Ratio of the inhibitory concentrations against rat liver DHFR and Pneumocystis carinii DHFR1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
6-substituted 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
AID56325Inhibitory concentration against dihydrofolate reductase DHFR from Toxoplasma gondii2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii.
AID233134Selectivity for dihydrofolate reductase enzyme in rat liver Toxoplasma gondii1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases.
AID560256Antimalarial activity against Plasmodium falciparum Kenyan isolates expressing DHFR Ser108Asn and Cys59Arg or Ser108Asn and Asn51Ile double mutant by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID488383Inhibition of human DHFR by spectrophotometric assay2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Synthesis and characterization of potent inhibitors of Trypanosoma cruzi dihydrofolate reductase.
AID559547Antimalarial activity against pyrimethamine-resistant Plasmodium falciparum V1S expressing DHFR quadruple mutant with point mutations at codons 108, 51, 59 and 164 gene by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation.
AID341478Inhibition of Mycobacterium avium DHFR using dihydrofolic acid substrate and NADPH cofactor2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID362429Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID94710Cytotoxic activity was evaluated against L tumor cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID55702In vitro inhibitory concentration against Pneumocystis carinii dihydrofolate reductase1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structural studies on bioactive compounds. 28. Selective activity of triazenyl-substituted pyrimethamine derivatives against Pneumocystis carinii dihydrofolate reductase.
AID58149Ratio of inhibition of dihydrofolate reductase(DHFR) from rat(rl) liver and Toxoplasma gondii(tg)1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
AID55699Concentration inhibiting Pneumocystis carinii dihydrofolate reductase1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
2,4-Diaminopyrido[3,2-d]pyrimidine inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii.
AID457207Selectivity ratio of IC50 for rat liver DHFR to IC50 for Pneumocystis carinii DHFR2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID56176Concentration inhibiting Toxoplasma gondii dihydrofolate reductase1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
2,4-Diaminopyrido[3,2-d]pyrimidine inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii.
AID219255Inhibitory compound against Wild-type human DHFR.1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID57961Inhibitory activity against dihydrofolate reductase (DHFR) from rat liver1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents.
AID229685Relative affinity for dihydrofolate reductase of rat liver and Toxoplasma gondii1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity.
AID55836Inhibitory activity against dihydrofolate reductase in Pneumocystis carinii at 37 centigrade.1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
AID409959Inhibition of bovine liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID57066Inhibitory concentration against Dihydrofolate reductase from Toxoplasma gondii (Toxoplasma gondii)2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.
AID235732Selectivity ratio between the IC50 values of DHFR from rat liver and DHFR from Pneumocystis carinii1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
AID747612Selectivity ratio of IC50 for human recombinant DHFR to IC50 for Pneumocystis jirovecii recombinant DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID232974Ratio of Dihydrofolate reductase inhibitory activity in rat to Pneumocystis carinii1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Structure-based design of selective inhibitors of dihydrofolate reductase: synthesis and antiparasitic activity of 2, 4-diaminopteridine analogues with a bridged diarylamine side chain.
AID57813In vitro inhibitory concentration against rat liver dihydrofolate reductase1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structural studies on bioactive compounds. 28. Selective activity of triazenyl-substituted pyrimethamine derivatives against Pneumocystis carinii dihydrofolate reductase.
AID214045Cytotoxic activity was evaluated against U87MG tumor cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID55698Compound was tested for inhibition activity against pneumocystis carinii (Pneumocystis carinii) Dihydrofolate reductase1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID57626Concentration required to inhibit the Pneumocystis carinii Dihydrofolate reductase by 50% was determined; Range: 34-662004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID233285Selectivity ratio is IC50 of rat liver DHFR to that of Pneumocystis carinii DHFR1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
AID101912Cytotoxic activity was evaluated against MCF-7/ADR+Reserpine cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID1623966Inhibition of Toxoplasma gondii DHFR-TS expressed in Escherichia coli BL21 competent cells using DHF as substrate preincubated for 15 mins followed by substrate and NADPH addition and measured after 60 mins by resazurin dye based diaphorase-coupled assay2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
AID219257Inhibitory constant for murine Wild-type dihydrofolate reductase (DHFR)2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Dihydrofolate reductase mutant with exceptional resistance to methotrexate but not to trimetrexate.
AID55689Inhibition of Pneumocystis carinii (pc) Dihydrofolate reductase1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Novel 2,4-diamino-5-substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductases.
AID186970Inhibition of U-46,619-induced contraction of Rat thoracic aorta in the presence of indomethacin1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and thromboxane A2 antagonist activity of N-benzyltrimetoquinol analogues.
AID233652Selectivity ratio of IC50(rat liver)/IC50(Pneumocystis carinii)2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Structural studies on bioactive compounds. 34. Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductase.
AID57610Concentration required to inhibit the Mycobacterium avium Dihydrofolate reductase by 50% was determined; Range: 1.3-1.72004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
AID94350Cytotoxic activity was evaluated against KB3-1 cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID56175Inhibitory activity against dihydrofolate reductase from Toxoplasma gondii1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
AID227227Selectivity ratio measured as the IC50 ratio of rlDHFR to the IC50 pcDHFR1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Synthesis and biological activities of conformationally restricted, tricyclic nonclassical antifolates as inhibitors of dihydrofolate reductases.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID457208Inhibition of Toxoplasma gondii DHFR at 37 degC by spectrophotometry2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID48922Minimum inhibitory concentration required to inhibit Candida albicans (in vitro)1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Selective inhibitors of Candida albicans dihydrofolate reductase: activity and selectivity of 5-(arylthio)-2,4-diaminoquinazolines.
AID56183Inhibitory activity against Dihydrofolate reductase from Toxoplasma gondii1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
6-substituted 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
AID57966Inhibitory activity against DHFR (Dihydrofolate reductase) from Rat liver1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Structure-based design of selective inhibitors of dihydrofolate reductase: synthesis and antiparasitic activity of 2, 4-diaminopteridine analogues with a bridged diarylamine side chain.
AID247223Growth inhibitory activity against human HCT116 cell line2004Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16
Structural studies on bioactive compounds. 39. Biological consequences of the structural modification of DHFR-inhibitory 2,4-diamino-6-(4-substituted benzylamino-3-nitrophenyl)-6-ethylpyrimidines ('benzoprims').
AID362430Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells in presence of folic acid2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID154150Cytotoxic Activity was evaluated against P388D1 cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID152988Cytotoxic activity was evaluated against P388/ADR + reserpine cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID234269Ratio of IC50 rat liver DHFR vs IC50 of Pneumocystis carinii DHFR1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
AID747608Inhibition of Mycobacterium avium DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID57074Inhibition of dihydrofolate reductase in Candida albicans (in vitro).1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Selective inhibitors of Candida albicans dihydrofolate reductase: activity and selectivity of 5-(arylthio)-2,4-diaminoquinazolines.
AID235655Selectivity index was determined by the ratio for IC50 of rat liver DHFR to the IC50 of Mycobacterium avium DHFR; Range: 3.4-7.22004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
AID57826Inhibitory activity against dihydrofolate reductase DHFR in rat liver2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Structural studies on bioactive compounds. 34. Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductase.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID362421Antiproliferative activity against human RFC expressing Chinese hamster PC43-10 cells2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID56983Tested for inhibitory activity against dihydrofolate reductase in human1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID232760Selectivity index measured as the ratio of IC50 for rat liver DHFR to IC50 for Toxoplasma gondii DHFR.1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Structural studies on bioactive compounds. 28. Selective activity of triazenyl-substituted pyrimethamine derivatives against Pneumocystis carinii dihydrofolate reductase.
AID231132Ratio of the inhibitory concentrations against rat liver DHFR and Toxoplasma gondii DHFR.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
6-substituted 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID57798Inhibitory activity against dihydrofolate reductase from rat liver1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines.
AID233653Selectivity ratio of IC50(rat liver)/IC50(Toxoplasma gondii)2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Structural studies on bioactive compounds. 34. Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductase.
AID56178Inhibition of Toxoplasma gondii dihydrofolate reductase1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
AID57069Inhibitory concentration against Dihydrofolate reductase from rat liver2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID232632Ratio of inhibitory activity against dihydrofolate reductase of rat liver to Toxoplasma gondii2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
AID56333Inhibitory activity against purified Dihydrofolate reductase from Toxoplasma gondii.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Nonclassical 2,4-diamino-6-(aminomethyl)-5,6,7,8-tetrahydroquinazoline antifolates: synthesis and biological activities.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID55839Inhibitory concentration against Pneumocystis carinii Dihydrofolate reductase1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Synthesis and biological activities of conformationally restricted, tricyclic nonclassical antifolates as inhibitors of dihydrofolate reductases.
AID57811Inhibition of rat liver dihydrofolate reductase1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
AID56172Inhibitory activity against Toxoplasma gondii dihydrofolate reductase.1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID55826Inhibition of dihydrofolate reductase DHFR in Pneumocystis carinii.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Structural studies on bioactive compounds. 34. Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductase.
AID362423Antiproliferative activity against human FRalpha expressing Chinese hamster RT16 cells2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID235379Selectivity ratio was measured as IC50 of rlDHFR/IC50 pcDHFR1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents.
AID55830Inhibitory activity against Dihydrofolate reductase from Pneumocystis carinii was evaluated using 90 uM dihydrofolic acid as substrate1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
AID229444Selectivity ratio as the ratio of IC50 value against recombinant human (rh) DHFR to that of pneumocystis carinii (pc ) DHFR.2002Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23
Synthesis of classical and nonclassical, partially restricted, linear, tricyclic 5-deaza antifolates.
AID233284Relative binding affinity for rat liver and Pneumocystis carinii DHFR1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID55696Inhibitory activity against Pneumocystis carinii dihydrofolate reductase.1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii.
AID362427Antiproliferative activity against human RFC and FRalpha expressing human KB cells2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID229684Relative affinity for dihydrofolate reductase of rat liver and Pneumocystis carinii1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID56984Tested for inhibitory concentration against human dihydrofolate reductase(DHFR)1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID56321Inhibitory concentration against Toxoplasma gondii Dihydrofolate reductase1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Synthesis and biological activities of conformationally restricted, tricyclic nonclassical antifolates as inhibitors of dihydrofolate reductases.
AID233636Ratio of inhibitory concentration of rat liver and Pneumocystis carinii DHFR.1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii.
AID78827Activity was evaluated against HCT-8 tumor cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID55687Inhibition of Pneumocystis carinii dihydrofolate reductase1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Synthesis of 5-methyl-5-deaza nonclassical antifolates as inhibitors of dihydrofolate reductases and as potential antipneumocystis, antitoxoplasma, and antitumor agents.
AID57984Inhibition of rat liver Dihydrofolate reductase1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Novel 2,4-diamino-5-substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductases.
AID55821Inhibitory activity against Dihydrofolate reductase from Pneumocystis carinii (pcDHFR)1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
AID56189Inhibitory activity against dihydrofolate reductase DHFR in Toxoplasma gondii.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Structural studies on bioactive compounds. 34. Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductase.
AID57076Inhibition of Dihydrofolate reductase enzyme from Candida albicans1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID234270Ratio of IC50 rat liver DHFR vs IC50 of Toxoplasma gondii DHFR1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
AID234748Selectivity ratio of Ki value against mutant DHFR and Wild-type DHFR.1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID232631Ratio of inhibitory activity against dihydrofolate reductase of rat liver to pneumocystis carinii2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
AID233682Selectivity ratio of rat liver(rl) / Toxoplasma gondii (tg)1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Synthesis and dihydrofolate reductase inhibitory activities of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates.
AID390569Inhibition of rat liver dihydrofolate reductase2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
N9-substituted 2,4-diaminoquinazolines: synthesis and biological evaluation of lipophilic inhibitors of pneumocystis carinii and toxoplasma gondii dihydrofolate reductase.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID362425Antiproliferative activity against human FRbeta expressing Chinese hamster D4 cells2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID55858Inhibition of Pneumocystis carinii dihydrofolate reductase1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases.
AID229445Selectivity ratio as the ratio of IC50 value against recombinant human (rh) DHFR to that of Toxoplasma gondii (tg) DHFR.2002Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23
Synthesis of classical and nonclassical, partially restricted, linear, tricyclic 5-deaza antifolates.
AID56329Inhibition of Toxoplasma gondii Dihydrofolate reductase1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases.
AID232975Ratio of Dihydrofolate reductase inhibitory activity in rat to Toxoplasma gondii1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Structure-based design of selective inhibitors of dihydrofolate reductase: synthesis and antiparasitic activity of 2, 4-diaminopteridine analogues with a bridged diarylamine side chain.
AID57592Inhibitory activity against Escherichia coli (ec) Dihydrofolate reductase2002Journal of medicinal chemistry, Nov-07, Volume: 45, Issue:23
Synthesis of classical and nonclassical, partially restricted, linear, tricyclic 5-deaza antifolates.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID232060Selectivity index was determined as ratio of IC50 against rat DHFR to that of IC50 against Pneumocystis carinii DHFR2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium.
AID1591491Inhibition of Pneumocystis jirovecii DHFR expressed in Escherichia coli Rosetta-gami B (DE3) assessed as reduction in consumption of NADPH using 18 uM DHFA as substrate2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection.
AID362426Antiproliferative activity against human FRbeta expressing Chinese hamster D4 cells in presence of folic acid2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID235504Selectivity ratio was measured as IC50 of rlDHFR/IC50 tgDHFR1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents.
AID747614Inhibition of human recombinant DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID56939Inhibition of Dihydrofolate reductase from Pneumocystis carinii (Pneumocystis carinii)2004Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14
Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.
AID219256Combined effect of active site mutation F31A and F34A on inhibitory effect for murine Wild-type dihydrofolate reductase (DHFR)2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Dihydrofolate reductase mutant with exceptional resistance to methotrexate but not to trimetrexate.
AID57797Compound was tested for inhibition activity against rat liver lipophilic Dihydrofolate reductase (DHFR).1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID409957Inhibition of bovine liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1797714Dihydrofolate Reductase (DHFR) Assay from Article 10.1021/jm070165j: \\Design and Synthesis of Classical and Nonclassical 6-Arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as Antifolates.\\2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as antifolates.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346101Human dihydrofolate reductase (Nucleoside synthesis and metabolism)1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (406)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990107 (26.35)18.7374
1990's199 (49.01)18.2507
2000's65 (16.01)29.6817
2010's28 (6.90)24.3611
2020's7 (1.72)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.43 (24.57)
Research Supply Index6.16 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index45.89 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials50 (11.85%)5.53%
Reviews49 (11.61%)6.00%
Case Studies3 (0.71%)4.05%
Observational0 (0.00%)0.25%
Other320 (75.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (17)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Comparative, Double-Blind Trial of Trimetrexate (CI-898) With Leucovorin Calcium Rescue Versus Trimethoprim / Sulfamethoxazole for Moderately Severe Pneumocystis Carinii Pneumonia in Patients With AIDS [NCT00001014]Phase 3302 participants InterventionalCompleted
An Open, Prospective, Multicenter Study of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia (PCP) and Serious Intolerance to Approved Therapies [NCT00000714]Phase 30 participants InterventionalCompleted
Phase I Study of High Dose Methotrexate With Simultaneous Trimetrexate and Leucovorin in Patients With Recurrent Osteosarcoma [NCT00119301]Phase 118 participants (Anticipated)Interventional2005-04-30Completed
A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia. [NCT00002102]0 participants InterventionalCompleted
Evaluation of Escalating Doses of Intravenous Trimetrexate as Therapy for Previously Untreated Pneumocystis Carinii Pneumonia in AIDS Patients With Subsequent Comparison of Intravenous and Oral Pharmacokinetics [NCT00000998]Phase 150 participants InterventionalCompleted
A Randomized, Comparative, Double-Blind Trial of Trimetrexate (CI-898) With Leucovorin Calcium Rescue Versus Trimethoprim / Sulfamethoxazole for Moderately Severe Pneumocystis Carinii Pneumonia in Patients With AIDS [NCT00001013]Phase 3364 participants InterventionalCompleted
A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia [NCT00002103]0 participants InterventionalCompleted
A Study of Trimetrexate With Leucovorin Rescue for AIDS Patients Who Are Refractory to Standard Therapies for Pneumocystis Carinii Pneumonia [NCT00000724]Phase 30 participants InterventionalCompleted
A Randomized, Comparative Trial of Trimetrexate With Leucovorin Rescue Versus Standard Anti-Pneumocystis Therapy Versus Standard Anti-Pneumocystis Therapy With High Dose Steroids for AIDS Patients With Pneumocystis Pneumonia Who Appear to Be Refractory to [NCT00000730]Phase 3240 participants InterventionalTerminated
A Study of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia [NCT00002434]0 participants InterventionalCompleted
A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia and Serious Intolerance to Approved Therapies [NCT00001016]Phase 30 participants InterventionalCompleted
Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia [NCT00002120]Phase 120 participants InterventionalCompleted
Phase II Trial of Trimetrexate and Leucovorin in The Treatment of Recurrent Childhood Acute Lymphoblastic Leukemia [NCT00002738]Phase 225 participants (Anticipated)Interventional1996-01-31Completed
A Study of Neutrexin (Trimetrexate Glucuronate) With Leucovorin Protection for Pediatric Patients (Ages 2-12) With Pneumocystis Carinii Pneumonia [NCT00002317]0 participants InterventionalCompleted
Phase II Trial of Trimetrexate (Neutrexin), 5-Fluorouracil and Leucovorin in Metastatic Colorectal Cancer [NCT00003446]Phase 20 participants Interventional1997-12-31Completed
A Phase II Window Study of Trimetrexate With Simultaneous Leucovorin Protection in the Treatment of Newly Diagnosed Patients With Metastatic Osteosarcoma [NCT00003776]Phase 20 participants Interventional1998-12-31Completed
Modulation of 5-Fluorouracil With Trimetrexate and Leucovorin in Advanced Pancreatic Cancer [NCT00002955]Phase 221 participants (Actual)Interventional1995-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]